
Please try another search
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
M. Kathleen Behrens | 69 | 2009 | Independent Chairwoman |
Hans Wigzell | 83 | 2010 | Chairman of Corporate Strategy Board & Independent Non-Employee Director |
Douglas S. Ingram | 62 | 2017 | CEO & Director |
Beverly L. Davidson | - | 2015 | Member of Strategic & Scientific Advisory Board |
Claude Nicaise | 72 | 2015 | Independent Non-Employee Director |
Steven Gray | - | 2019 | Member of Scientific Advisory Board |
Angela J. Russell | - | 2020 | Member of Scientific Advisory Board |
Stephen L. Mayo | 63 | 2021 | Independent Director |
Carsten Bonnemann | - | 2019 | Member of Scientific Advisory Board |
Joy A. Cavagnaro | - | 2019 | Member of Scientific Advisory Board |
Michael Chambers | 50 | 2022 | Independent Director |
Matthew Wood | - | 2017 | Member of Strategic & Scientific Advisory Board |
Louis M. Kunkel | - | 2015 | Member of Strategic & Scientific Advisory Board |
Kenneth H. Fischbeck | - | 2017 | Member of Strategic & Scientific Advisory Board |
Kay Davies | - | 2019 | Member of Scientific Advisory Board |
Annemieke Aartsma-Rus | - | 2019 | Member of Scientific Advisory Board |
Kathryn J. Boor | 66 | 2022 | Independent Director |
Deirdre P. Connelly | 64 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review